Kilitch Drugs (India) Limited — Important, 12-11-2024: Financial Result Updates

Kilitch Drugs (India) Ltd has announced a board meeting on which it reviewed its consolidated financial results for the quarter ended 30th September 2024.

Total consolidated revenue reached ₹5,263.91 crore, reflecting a year-over-year increase of approximately 26% driven by strong sales in the export market and new product registrations. The net profit for the same period was ₹861.18 crore, up from ₹509.36 crore, resulting in an EPS of ₹5.36, indicating improved profitability largely due to operational efficiencies despite rising material costs.

Operational costs increased by about 23% year-over-year, primarily due to higher material prices and salary increments, yet the company showed a solid gross profit margin. The balance sheet appears healthy with total assets of ₹25,942.53 crore and a debt-to-equity ratio that suggests adequate financial leverage.

Strategically, Kilitch is focusing on expanding its product offerings and entering new markets, which may enhance investor sentiment. Given the robust financial performance and future growth potential, the outlook leans towards a buy for investors looking at long-term gains.